Publications by authors named "Kelly Oliner"

Claim this Profile
C
Challenges to Innovation Arising from Current Companion Diagnostic Regulations and Suggestions for Improvements.
Kelly S Oliner, Michelle Shiller, Peter Schmid, Marianne J Ratcliffe, Aaron J Schetter

Clin Cancer Res· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of tumour RAS/BRAF status in a first-line study of panitumumab + FOLFIRI in patients with metastatic colorectal cancer.
Meinolf Karthaus, Ralf-Dieter Hofheinz, Laurent Mineur, Henry Letocha, Richard Greil, Kelly S Oliner

Br J Cancer· November 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PARTNER: An open-label, randomized, phase 2 study of docetaxel/cisplatin chemotherapy with or without panitumumab as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck.
Lori J Wirth, Shaker Dakhil, Gabriela Kornek, Rita Axelrod, Douglas Adkins, Kelly S Oliner

Oral Oncol· October 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic impact of tumor MET expression among patients with stage IV gastric cancer: a Danish cohort study.
Rune Erichsen, Michael A Kelsh, Kelly S Oliner, Karsten B Nielsen, Trine Frøslev

Ann Epidemiol· July 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Analysis of KRAS/NRAS Mutations in a Phase III Study of Panitumumab with FOLFIRI Compared with FOLFIRI Alone as Second-line Treatment for Metastatic Colorectal Cancer.
Marc Peeters, Kelly S Oliner, Timothy J Price, Andrés Cervantes, Alberto F Sobrero

Clin Cancer Res· December 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tumor MET Expression and Gene Amplification in Chinese Patients with Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer.
Zhi Peng, Zhongwu Li, Jing Gao, Ming Lu, Jifang Gong, Kelly S Oliner

Mol Cancer Ther· November 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Blockade of interferon-γ normalizes interferon-regulated gene expression and serum CXCL10 levels in patients with systemic lupus erythematosus.
Andrew A Welcher, Michael Boedigheimer, Alan J Kivitz, Zahir Amoura, Jill Buyon, Kelly S Oliner

Arthritis Rheumatol· October 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Extended RAS analysis for anti-epidermal growth factor therapy in patients with metastatic colorectal cancer.
J Randolph Hecht, Jean-Yves Douillard, Lee Schwartzberg, Axel Grothey, Scott Kopetz, Kelly S Oliner

Cancer Treat Rev· September 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rilotumumab exposure-response relationship in patients with advanced or metastatic gastric cancer.
Sameer Doshi, Per Olsson Gisleskog, Yilong Zhang, Min Zhu, Kelly S Oliner

Clin Cancer Res· June 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Panitumumab plus radiotherapy versus chemoradiotherapy in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-2): a randomised, controlled, open-label phase 2 trial.
Jordi Giralt, Jose Trigo, Sandra Nuyts, Mahmut Ozsahin, Krzysztof Skladowski, Kelly S Oliner

Lancet Oncol· February 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Chemoradiotherapy with or without panitumumab in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-1): a randomised, controlled, open-label phase 2 trial.
Ricard Mesía, Michael Henke, Andre Fortin, Heikki Minn, Alejandro Cesar Yunes Ancona, Kelly S Oliner

Lancet Oncol· February 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of an integrated clinical workflow for targeted next-generation sequencing of low-quality tumor DNA using a 51-gene enrichment panel.
Ashish Choudhary, Elizabeth Mambo, Tiffany Sanford, Michael Boedigheimer, Brian Twomey, Kelly S Oliner

BMC Med Genomics· November 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized phase Ib/II trial of rilotumumab or ganitumab with panitumumab versus panitumumab alone in patients with wild-type KRAS metastatic colorectal cancer.
Eric Van Cutsem, Cathy Eng, Elzbieta Nowara, Anna Swieboda-Sadlej, Niall C Tebbutt, Kelly S Oliner

Clin Cancer Res· August 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study.
Timothy Iveson, Ross C Donehower, Irina Davidenko, Sergey Tjulandin, Andrzej Deptala, Kelly S Oliner

Lancet Oncol· August 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer.
Lee S Schwartzberg, Fernando Rivera, Meinolf Karthaus, Gianpiero Fasola, Jean-Luc Canon, Kelly S Oliner

J Clin Oncol· July 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Detection of circulating tumor DNA in early- and late-stage human malignancies.
Chetan Bettegowda, Mark Sausen, Rebecca J Leary, Isaac Kinde, Yuxuan Wang, Kelly S Oliner

Sci Transl Med· February 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population pharmacokinetics of rilotumumab, a fully human monoclonal antibody against hepatocyte growth factor, in cancer patients.
Min Zhu, Sameer Doshi, Per O Gisleskog, Kelly S Oliner, Juan Jose Perez Ruixo

J Pharm Sci· January 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer.
Jean-Yves Douillard, Kelly S Oliner, Salvatore Siena, Josep Tabernero, Ronald Burkes

N Engl J Med· September 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial.
Jan B Vermorken, Jan Stöhlmacher-Williams, Irina Davidenko, Lisa Licitra, Eric Winquist, Kelly S Oliner

Lancet Oncol· July 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Massively parallel tumor multigene sequencing to evaluate response to panitumumab in a randomized phase III study of metastatic colorectal cancer.
Marc Peeters, Kelly S Oliner, Alex Parker, Salvatore Siena, Eric Van Cutsem

Clin Cancer Res· April 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeted MET inhibition in castration-resistant prostate cancer: a randomized phase II study and biomarker analysis with rilotumumab plus mitoxantrone and prednisone.
Charles J Ryan, Mark Rosenthal, Siobhan Ng, Joshi Alumkal, Joel Picus, Kelly S Oliner

Clin Cancer Res· January 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers.
Luis A Diaz, Richard T Williams, Jian Wu, Isaac Kinde, J Randolph Hecht, Kelly S Oliner

Nature· June 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic and predictive significance of plasma HGF and IL-8 in a phase III trial of chemoradiation with or without tirapazamine in locoregionally advanced head and neck cancer.
Quynh-Thu Le, Richard Fisher, Kelly S Oliner, Richard J Young, Hongbin Cao

Clin Cancer Res· March 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase II study evaluating the efficacy and safety of AMG 102 (rilotumumab) in patients with recurrent glioblastoma.
Patrick Y Wen, David Schiff, Timothy F Cloughesy, Jeffrey J Raizer, John Laterra, Kelly S Oliner

Neuro Oncol· April 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tumor KRAS status predicts responsiveness to panitumumab in Japanese patients with metastatic colorectal cancer.
Toshihiko Doi, Makoto Tahara, Takayuki Yoshino, Kentaro Yamazaki, Tomohide Tamura, Kelly Smith Oliner

Jpn J Clin Oncol· February 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis